Pfizer Inc. (PFE)

Oncology Corporate Profile

Stock Performance


HQ Location

235 East 42nd Street
New York, NY 10017

Company Description

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.


Brand Generic Indication
Aromasin®exemestaneAromasin® is indicated for adjuvant treatment of postmenopausal women with estrogen receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Aromasin® for completion of a total of five consecutive years of adjuvant hormonal therapy. Aromasin® is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Bavencio®avelumabBavencio® is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Besponsa®inotuzumab ozogamicinBesponsa® is a CD22-directed antibody-drug conjugate (ADC) indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Bosulif®bosutinibBosulif® is a kinase inhibitor indicated for the treatment of adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML). This indication is approved under accelerated approval based on molecular and cytogenetic response rates. Continued approval for this indication may be contingent upon verification and confirmation of clinical benefit in an ongoing long-term follow up trial; Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Camptosar®irinotecan hydrochlorideCamptosar® Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. Camptosar® is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
Ellence®epirubicin hydrochlorideEllence® Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Emcyt®estramustine phosphate sodiumEmcyt® Capsules are indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.
Ibrance®palbociclibIbrance® is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or fulvestrant in women with disease progression following endocrine therapy.
Ibrance®palbociclibIbrance® is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with letrozole as initial endocrine based therapy in postmenopausal women (1), or fulvestrant in women with disease progression following endocrine therapy.
Inlyta®axitinibInlyta® is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.
Mylotarg™gemtuzumab ozogamicinMylotarg™ is a CD33-directed antibody-drug conjugate indicated for tge treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and the treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older.
Neumega®oprelvekinNeumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle. Neumega® is not indicated following myeloablative chemotherapy. The safety and effectiveness of NEUMEGA have not been established in pediatric patients.
Relistor®methylnaltrexone bromideRelistor® is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of Relistor® beyond four months has not been studied.
RetacritRetacrit is an erythropoiesis-stimulating agent (ESA) indicated for:
• Treatment of anemia due to
o Chronic Kidney Disease (CKD) in patients on dialysis and not on
o Zidovudine in patients with HIV-infection.
o The effects of concomitant myelosuppressive chemotherapy, and upon
initiation, there is a minimum of two additional months of planned
• Reduction of allogeneic RBC transfusions in patients undergoing elective,
noncardiac, nonvascular surgery.
Limitations of Use
RETACRIT has not been shown to improve quality of life, fatigue, or patient
RETACRIT is not indicated for use:
• In patients with cancer receiving hormonal agents, biologic products, or
radiotherapy, unless also receiving concomitant myelosuppressive
• In patients with cancer receiving myelosuppressive chemotherapy when the
anticipated outcome is cure.
• In patients with cancer receiving myelosuppressive chemotherapy in whom
the anemia can be managed by transfusion.
• In patients scheduled for surgery who are willing to donate autologous
• In patients undergoing cardiac or vascular surgery.
• As a substitute for RBC transfusions in patients who require immediate
correction of anemia.
Sutent®sunitinib malateSutent® is a kinase inhibitor indicated for the treatment of: gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate; advanced renal cell carcinoma (RCC); progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.
Talzenna™ talazoparibTalzenna™ is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for Talzenna™.
Torisel®temsirolimusTorisel® is indicated for the treatment of advanced renal cell carcinoma.
Trelstar® Depottriptorelin pamoateTrelstar® Depot is indicated in the palliative treatment of advanced prostate cancer. It offers an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.
Vizimpro®dacomitinibVizimpro® is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Xalkori®crizotinibXalkori® is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test; metastatic NSCLC whose tumors are ROS1-positive.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
dacomitinib / PF-00299804pan-HER inhibitor1st line EGFR mutant Non Small Cell Lung CancerIII
avelumab / PF-06834635Anti PD-L1 Inhibitor1st line Gastric cancerIII
PF-05280014erbB2 TK Inhibitor1st line metastatic Breast cancerIII
avelumab / PF-06834635Anti PD-L1 Inhibitor1st line Non Small Cell Lung Cancer (NSCLC)III
avelumab / PF-06834635Anti PD-L1 Inhibitor1st line Ovarian cancerIII
avelumab / PF-06834635Anti PD-L1 Inhibitor1st line Renal cell carcinoma (RCC)III
avelumab / PF-06834635Anti PD-L1 Inhibitor2nd line Non Small Cell Lung Cancer (NSCLC)III
avelumab / PF-06834635Anti PD-L1 Inhibitor2nd line Urothelial cancerIII
avelumab / PF-06834635Anti PD-L1 Inhibitor3rd line Gastric cancerIII
inotuzumab ozogamicinCD22-targeted cytotoxic agentAcute Lymphocytic Leukemia (ALL)III
inotuzumab ozogamicin / PF-5208773antibody drug conjugate (anti-CD22 monoclonal antibody linked to CalichDMH - humanized)Acute Lymphocytic Leukemia (ALL)III
tanezumabnerve growth factor inhibitorCancer painIII
avelumab / PF-06834635Anti PD-L1 InhibitorPlatinum-resistant/refractory Ovarian cancerIII
avelumab / PF-06834635Anti PD-L1 InhibitorSquamous cell carcinoma of the Head & NeckIII
Bosulif® / bosutinibAbl and src-family kinase Inhibitor1st line chronic myelogenous LeukemiaIII
Ibrance® / palbociclibCDK 4,6 kinase inhibitorEarly Breast cancer in adjuvant settingIII
Ibrance® / palbociclibCDK 4,6 kinase inhibitorHigh risk early Breast cancerIII
Inlyta® / axitinibVEGF tyrosine kinase InhibitorRenal cell carcinoma (RCC)III
Sutent® / sunitinibmultiple tyrosine kinase inhibitorAdjuvant Renal cell cancer (RCC)III
Xtandi® / enzalutamideAndrogen receptor inhibitorMetastatic hormone-sensitive Prostate cancerIII
Xtandi® / enzalutamideAndrogen receptor inhibitorNon-metastatic castrate resistant Prostate cancerIII
Xtandi® / enzalutamideAndrogen receptor inhibitorNon-metastatic high risk hormone-sensitive Prostate cancerIII
Xtandi® / enzalutamideAndrogen receptor inhibitorTriple negative Breast cancerIII
glasdegib / PF-04449913SMO (smoothened) antagonistAcute Myelogenous Leukemia (AML)II
lorlatinib / PF-06463922ALK InhibitorALK Non Small Cell Lung Cancer (NSCLC)II
talazoparibPARP inhibitorBreast cancerII
Ibrance® / palbociclib (+ letrozole)CDK 4,6 kinase inhibitorBreast cancerII
Xtandi® / enzalutamideAndrogen receptor inhibitorER/PR+ & HER2 normal and HER2+ amplified Breast cancerII
Xtandi® / enzalutamideAndrogen receptor inhibitorHepatocellular carcinoma (HCC)II
avelumab (+ axitinib) / PF-06834635Anti PD-L1 Inhibitor1st line Renal cell carcinoma (RCC)I
PF-05212384PI3K/mTOR inhibitorVarious cancer typesI
PF-050825664-1BB agonist monoclonal antibodyVarious cancer typesI
gedatolisib / PF-05212384PI3K/mTOR inhibitorVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

Pfizer Scraps Cholesterol Fighter, Trims Profit Forecast

11/1/2016 04:34 pm

(New York Times/Reuters) Nov 1, 2016 - Pfizer Inc said it halted development of a costly new type of cholesterol fighter because disappointing clinical trial data and an unfavorable market for similar approved drugs bode poorly for its injectable medicine.

Novartis Breast Cancer Drug Gets FDA Fast Track, Takes On Pfizer

11/1/2016 04:08 pm

( Nov 1, 2016 - The U.S. Food and Drug Administration gave fast-track review status to Novartis's medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer as the Swiss company seeks to challenge Pfizer's Ibrance drug.

Pfizer to Launch Cheaper Version Of J&J Immune Drug Remicade

10/18/2016 04:53 pm

( Press) Oct 18, 2016 - Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson & Johnson's blockbuster immune disorder drug, Remicade.

Transgene Links With Merck, Pfizer For Head And Neck Cancer Trial

10/12/2016 04:28 pm

(PharmaTimes [UK]) Oct 12, 2016 - Transgene has entered into collaboration agreement with Merck KGaA and Pfizer under which it will sponsor an early-stage study testing a potential new combination treatment for head and neck cancer.

Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)

10/10/2016 03:50 pm

(Pfizer) Oct 9, 2016 - Pfizer Inc. today announced data from an ongoing, investigational Phase 1b study of INLYTA® (axitinib) combined with the checkpoint inhibitor pembrolizumab (A4061079, NCT02133742), a PD-1 inhibitor known as KEYTRUDA® and marketed by Merck, known as MSD outside the United States and Canada, in treatment-naïve patients with advanced renal cell carcinoma (RCC).

Exelixis and Pfizer Drugs Compete In Kidney Cancer Trial

10/10/2016 02:46 pm

(Reuters) Oct 10, 2016 - Exelixis's drug Cabometyx outperformed Pfizer's Sutent in a clinical study for the treatment of metastatic kidney cancer, suggesting it has the potential to become a first-line treatment, researchers said on Monday.

Novartis Targets Breast Cancer Drug Approval to Take on Pfizer

10/10/2016 02:45 pm

(Bloomberg) Oct 8, 2016 - An experimental Novartis AG treatment for a form of advanced breast cancer slashed the risks of death and the disease progressing in a study, paving the way for the Swiss drugmaker to seek regulatory approval in the U.S. and Europe by the end of the year.

Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress

9/28/2016 05:00 pm

(Pfizer) Sept 28, 2016 - Pfizer Inc. today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016.

Pfizer Completes Acquisition of Medivation

9/28/2016 04:51 pm

(StreetInsider) Sept 28, 2016 - Pfizer Inc. today announced the successful completion of its acquisition of Medivation, Inc. As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for $81.50 per share in cash, without interest, subject to any required withholding of taxes.

Pfizer Won’t Pursue a Split of Established and New Medical Lines

9/26/2016 04:30 pm

(MorningStar/Dow Jones Newswires) Sept 26, 2016 - Pfizer Inc. said Monday that it would remain a single company, deciding not to split its established and new medical lines into separate companies.

Regeneron, Teva Take Aim At Lilly/Pfizer Pain Drug

9/20/2016 05:22 pm

(The Daily Mail/Reuters) Sept 20, 2016 - Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

FDA Panel Recommends Dropping Serious Warning on Pfizer's Chantix

9/15/2016 05:25 pm

(Reuters) Sept 14, 2016 - A serious warning on Pfizer Inc's quit smoking drug should be removed, 10 of 19 independent panelists to the U.S. Food and Drug Administration recommended on Wednesday, after reviewing additional trial data on the controversial treatment.

OncoImmune Licenses ONC-392 to Pfizer for Up to $250M

9/15/2016 05:05 pm

(Genetic Engineering & Biotechnology News) Sept 15, 2016 - OncoImmune said today it agreed to license its preclinical anti-CTLA4 monoclonal antibody ONC-392 to Pfizer, in a deal that could generate up to $250 million in upfront and milestone payments for OncoImmune.

FDA Staff Flags Concerns About Pfizer's Quit-Smoking Drug Study

9/12/2016 05:08 pm

(Reuters) Sept 12, 2016 - U.S. Food and Drug Administration scientists have expressed concerns about a post-marketing study of Pfizer Inc's drug Chantix, which is aimed at helping smokers quit, according to documents posted on the regulator's website on Monday.

Clinton’s Drug Proposals ‘Very Negative,’ Pfizer CEO Says

9/9/2016 04:31 pm

(Bloomberg) Sept 8, 2016 - The head of Pfizer Inc., America’s biggest drugmaker, said that Democratic presidential nominee Hillary Clinton’s proposals to contain the price of pharmaceuticals would be “very negative” for the industry and are a step toward single-payer health care.

Pfizer's Xalkori Cleared for ROS1-Positive Lung Cancer

9/1/2016 04:09 pm

(PharmaTimes [UK]) Sept 1, 2016 - The European Commission has widened the scope of Pfizer's Xalkori to include the treatment of adults with ROS1-positive advanced non-small-cell lung cancer (NSCLC).

Pfizer to Buy Antibiotics Business From AstraZeneca

8/24/2016 04:19 pm

(FoxNews/Reuters) Aug 24, 2016 - Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc in a deal that could be valued at more than $1.5 billion.

With $14 Billion Purchase, Pfizer Signals That Cancer Drug Prices Will Remain High

8/22/2016 04:02 pm

(Forbes) Aug 22, 2016 - Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation’s prostate cancer drug, Xtandi, which costs $120,000 a year and generated $2.2 billion in sales over its last four quarters.

Pfizer to Buy Cancer Drug Maker in $14 Billion Deal

8/22/2016 04:02 pm

(New York Times/DealBook) Aug 22, 2016 - Medivation, which makes treatments for prostate and breast cancers, has finally found its buyer in a fellow American drug maker, Pfizer.

Pfizer Trumps Sanofi With Medivation Deal for $14 Billion

8/22/2016 11:53 am

(Bloomberg) Aug 22, 2016 - Pfizer Inc. agreed to buy Medivation Inc. in a deal that values the company at about $14 billion and leaves French drugmaker Sanofi jilted.

Pfizer Chief Plays Down Prospect Of Split

8/3/2016 03:58 pm

(Financial Times) Aug 2, 2016 - Pfizer’s chief executive appeared to play down the prospect of splitting the drugmaker into two discrete companies, arguing the case for a break-up had become “more complicated” in recent months.

Pfizer Acquires Bamboo Therapeutics To Beef Up Gene Therapy Arsenal

8/1/2016 04:25 pm

(Reuters) Aug 1, 2016 - Pfizer Inc said it had acquired privately held gene therapy developer Bamboo Therapeutics Inc in a deal worth up to $645 million to boost its presence in the treatment of rare diseases.

Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology

7/28/2016 03:57 pm

(4-traders) July 28, 2016 - Companies plan to advance Western Oncolytics' lead preclinical therapy into human testing; potential combination of WO-12 with Pfizer's oncology pipeline could enhance therapeutic benefit in patients.

Pfizer Cleared to Buy Nanotech Drug Firm Bind Therapeutics

7/28/2016 03:57 pm

(Morningstar/Dow Jones Newswires) July 27, 2016 - The sale price means the business, which develops drug treatments that use nanoparticles to treat cancer, will continue in Pfizer's hands.

To Split Or Not To Split? One Wall Street Wag Thinks Pfizer May Remain Intact

7/19/2016 04:37 pm

(STAT/Pharmalot) July 18, 2016 - After its deal to acquire Allergan fell apart three months ago, Pfizer executives indicated they may split the company into different parts.

FDA Warns Questionable Cancer Clinic Again for CGMP Violations

6/22/2016 02:00 pm

(Regulatory Affairs) June 21, 2016 - A little more than a month after the US Food and Drug Administration (FDA) was overruled by a judge to allow a college student with terminal cancer to re-start a clinical trial, in which he’s the only patient, FDA has issued a warning letter to the manufacturing facility linked to the trial, noting serious current good manufacturing practice (CGMP) violations.

Study Finds Patient Navigators Improve Comprehensive Cancer Screening Rates

6/21/2016 12:01 pm

(Mass General) June 20, 2016 - A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators – individuals who assist patients in receiving health care services – may improve comprehensive cancer screening rates among patient populations not likely to receive recommended screenings.

Novartis Presents Data Showing Jakavi® Is Superior To Best Available Therapy In Patients With Less Advanced Polycythemia Vera (PV)

6/10/2016 12:00 pm

(Novartis) June 10, 2016 - Novartis today announced Phase III data from RESPONSE-2 showing that Jakavi® (ruxolitinib) helped patients with polycythemia vera (PV), who did not have an enlarged spleen and were resistant to or intolerant of hydroxyurea, achieve superior hematocrit control compared to best available therapy (BAT) at 28 weeks (62.2% vs 18.7%, respectively; p<0.0001).

Increased Testing Needed To Combat Rising Syphilis Infections

6/8/2016 12:00 pm

(USA Today) June 8, 2016 - As rates of syphilis infections in the United States continue to rise, doctors should increase screening for the disease among high-risk individuals, according to new recommendations from a government-backed health panel.

Myriad On Genetic Testing For Cancer Risk: Insurance Gap Is A ‘Crisis'

6/6/2016 02:02 pm

(Forbes) June 6, 2016 - Myriad is among several companies that are facing a headwind of resistance from, among others, the insurance industry, which has doubts about the value of testing so many genes.

Durvalumab Monotherapy Demonstrates Efficacy In Urothelial Bladder Cancer

6/5/2016 06:02 pm

( June 5, 2016 - Data show objective response rate (ORR) of 31% in all evaluable patients and 46% in patients with PD-L1-high-expressing tumors.

Novel Daratumumab-Based Regimen Slows Multiple Myeloma Progression

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 – Initial findings from a pivotal phase III trial showed that daratumumab (DARZALEX) added to a standard two-drug regimen (bortezomib and dexamethasone) markedly improved outcomes for patients with recurrent or refractory multiple myeloma.

Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 - A randomized phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole (Femara) from 5 to 10 years.

Novartis Data Show More Than 50 Percent Of Eligible Ph+ CML Patients Maintain Treatment-free Remission (TFR) After Stopping Tasigna®

6/4/2016 05:03 pm

(Benzinga) June 4, 2016 - Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program.

Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability

6/4/2016 05:03 pm

(Juno) June 4, 2016 - Durable remissions in adult ALL, NHL, and CLL patients with JCAR014; 100% complete molecular remission as measured by flow cytometry in pediatric ALL patients with JCAR017 and fludarabine/cyclophosphamide.

Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

5/27/2016 10:02 am

(StreetInsider) May 27, 2016 - Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.

NICE Turns Down Lilly's Lung Cancer Drug Portrazza

5/27/2016 06:05 am

(PharmaTimes [UK]) May 27, 2016 - The National Institute for Health and Care Excellence has published draft guidelines rejecting the drug, in combination with gemcitabine and cisplatin, for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy.

Sanofi Wins FDA Panel’s Backing for Once-Daily Diabetes Combo

5/26/2016 12:00 pm

(Bloomberg) May 25, 2016 - Sanofi’s once-a-day shot for diabetes that combines two drugs should be approved for sale, a group of advisers to the U.S. Food and Drug Administration said.

New Positive Phase III Study For Ner1006 - The First 1 Litre Peg-Based Bowel Preparation

5/25/2016 11:01 am

(Norgine) May 24, 2016 - Study met both primary endpoints demonstrating non-inferiority in overall bowel cleansing and superiority in ‘Excellent plus Good’ cleansing of the ascending colon.

Continuing Nivolumab Beyond Progression May Be Worthwhile in Kidney Cancer

5/20/2016 11:03 am

(Medscape Medical News/Reuters Health) May 19, 2016 - Nivolumab can be effective in patients with metastatic renal cell carcinoma (RCC) treated beyond first progression, according to a subgroup analysis of a phase 2 clinical trial.

Oncologists: Medicare Proposal Will Limit Cancer Patients’ Access to Drugs, Endanger Chances of Healing

5/18/2016 11:05 am

(cCARE) May 17, 2016 - A Medicare proposal for testing new ways to pay for drugs may jeopardize cancer patients’ health and chances of recovery, may also create two unequal classes of patients, and could further result in more patients being forced to seek costlier treatment in hospitals, says one of California’s largest private oncology practices.

Study Advances Understanding of Colon Cancer and Colitis

5/18/2016 11:04 am

(UC Riverside/UCR Today) May 17, 2016 - UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.

JOP Editorial Examines Bundled Payment Approaches in Oncology, Proposes Inclusion of Value-based Pathways to Enhance System

5/13/2016 11:04 am

(ASCO in Action) May 12, 2016 - On May 12, the Journal of Oncology Practice (JOP) published an online editorial that examines bundled payment approaches in oncology and proposes the incorporation of a value-based pathways model to enhance the physician reimbursement system.

NHS England Reveals 'World-Class' Cancer Care Plans

5/12/2016 12:02 pm

(Daily Mail/Press Association [UK]) May 12, 2016 - People with a suspected case of cancer will be given a definitive diagnosis within four weeks under ambitious new plans to provide "world-class" cancer care in England.

AACR Congratulates Newest National Academy of Sciences Members

5/5/2016 11:04 am

(AACR) May 5, 2016 - The American Association for Cancer Research (AACR) congratulates its 10 members who have been elected to the National Academy of Sciences, including Fellows of the AACR Academy Anton Berns, PhD; Peter A. Jones, PhD, DSc; and Kenneth W. Kinzler, PhD.

New Treatment for Rare White Blood Cell Cancer

4/29/2016 11:01 am

(EMA) Apr 29, 2016 - The European Medicines Agency (EMA) has recommended extending the authorised indication of Gazyvaro (obinutuzumab) to treat patients with follicular lymphoma. The medicine is to be used in combination with bendamustine in patients who were previously treated with chemotherapy.

New Model Predicts Survival In Italian, Taiwanese with HCC

4/27/2016 11:05 am

(Healio) Apr 26, 2016 - Researchers recently developed the ITA.LI.CA prognostic system, which accurately predicted survival of Italian and Taiwanese patients with hepatocellular carcinoma, using data from the Italian Liver Cancer database. Further, the system may also serve as a potential use for designating treatment.

Tomosynthesis Beneficial for Dense, Nondense Breasts

4/27/2016 11:05 am

(Doctors Lounge/HealthDay News) Apr 26, 2016 - The addition of tomosynthesis to mammography is beneficial for women with dense and nondense breasts, and the readability of dense breast notifications vary by state, according to two research letters published in the April 26 issue of the Journal of the American Medical Association.

Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk, Penn Study Suggests

4/27/2016 11:04 am

(Penn Medicine) Apr 26, 2016 - Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient's risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in PLOS Medicine.

Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of Concordance

4/18/2016 11:00 am

(AACR) Apr 18, 2016 - Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health care providers may someday be able to use these tests interchangeably when determining which patients will respond best to anti-PD-L1/PD-1 immunotherapeutic drugs, according to research presented here at the AACR Annual Meeting 2016, April 16-20.